A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.
暂无分享,去创建一个
M. Dyer | T. Brümmendorf | J. Radford | C. Fegan | W. Brugger | S. Stilgenbauer | L. Drew | A. Kater | W. Shao | P. Brossart | A. Davies | S. Rule | M. Kaiser | J. Birkett | S. Kayser | Justin Cidado